drugset
Drugs / AK146D1
last change Aug 2026 re-read 9 days ago

AK146D1

also known as AK146D1 for injection
Developed for
cancer · female breast carcinoma · non-small cell lung carcinoma · urothelial carcinoma
Investigated by
Akeso

Trials 5

today NCT07669779 · Ph 2 NCT07636772 · Ph 2 NCT07591090 · Ph 2 NCT07067567 · Ph 1 NCT06929663 · Ph 1
202620272028
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 12 trials
Phase 1 NCT07067567 Aug 2025 → Nov 2026 expected cancer Akeso Recruiting No outcome recorded
Phase 1 NCT06929663 Jul 2025 → Nov 2026 expected cancer Akeso Recruiting No outcome recorded
Phase 23 trials
Phase 2 NCT07669779 Jul 2026 → Aug 2027 expected non-small cell lung carcinoma Akeso Recruiting No outcome recorded
Phase 2 NCT07636772 Jun 2026 → Aug 2028 expected urothelial carcinoma Akeso Not yet recruiting No outcome recorded
Phase 2 NCT07591090 Jun 2026 → Sep 2027 expected female breast carcinoma Akeso Not yet recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2026-03-24 Akeso Regulatory IO2.0+ADC2.0系列疗法组合II期临床开展！康方AK146D1及AK138D1联合卡度尼利/依沃西及自研高潜力药物治疗实体瘤 akesobio.com ↗

All press releases naming this drug 4 releases

DateIssuerRelease

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as AK146D1 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07669779 ↗
4

NCT07067567 ↗

NCT07636772 ↗

NCT07591090 ↗

NCT06929663 ↗
Known as AK146D1 for injection “AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate” NCT06929663 ↗
Route Intravenous “Participants in this group will receive AK146D1 combined with AK112 as i.v. infusion.” NCT07591090 ↗